Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 31, 2023 - Issue 8
Submit an article Journal homepage
1,680
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Suprachoroidal CLS-TA with and without Systemic Corticosteroid and/or Steroid-Sparing Therapy: A Post-Hoc Analysis of the Phase 3 PEACHTREE Clinical Trial

Pauline T. Merrilla Illinois Retina Associates, Chicago, IL, USA;b Rush University Department of Ophthalmology, Chicago, IL, USAView further author information
, MD,
Christopher R. Henryc Retina Consultants of Texas, Houston, TX, USA;d Blanton Eye Institute, Houston Methodist Hospital, Houston, TX, USAView further author information
, MD,
Quan Dong Nguyene Stanford University Medical Center, Palo Alto, CA, USA;f Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USAView further author information
, MD, MSc,
Ashvini Reddyg Athena Eye Institute, San Antonio, TX, USAView further author information
, MD,
Barry Kapikh Clearside Biomedical, Alpharetta, GA, USAView further author information
, MS &
Thomas A. Ciullah Clearside Biomedical, Alpharetta, GA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-5557-6777View further author information
, MD, MBAORCID Icon
Pages 1579-1586 | Received 19 Jan 2021, Accepted 05 Jul 2021, Published online: 18 Aug 2021

References

  • Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5–6):303–308. doi:10.1007/BF00163549.
  • Durrani OM, Tehrani NN, Marr JE, et al. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi:10.1136/bjo.2003.037226.
  • Rothova A, Suttorp-van Schulten MS, Frits Treffers W, et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332.
  • Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, et al. Benefits of systemic anti-inflammatory therapy versus fluocinolone acetonide intraocular implant for intermediate uveitis, posterior uveitis, and panuveitis: fifty-four-month results of the multicenter uveitis steroid treatment (MUST) trial and follow-up study. Ophthalmology. 2015;122(10):1967–1975. doi:10.1016/j.ophtha.2015.06.042.
  • Multicenter Uveitis Steroid Treatment Trial Research G, Kempen JH, Altaweel MM, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–1926. doi:10.1016/j.ophtha.2011.07.027.
  • Sen HN, Vitale S, Gangaputra SS, et al. Periocular corticosteroid injections in uveitis: effects and complications. Ophthalmology. 2014;121(11):2275–2286. doi:10.1016/j.ophtha.2014.05.021.
  • Writing Committee For The Multicenter Uveitis Steroid Treatment T, Follow-up Study Research G, Kempen JH, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993–2005. doi:10.1001/jama.2017.5103.
  • Chen M, Li X, Liu J, et al. Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. J Control Release. 2015;203:109–117. doi:10.1016/j.jconrel.2015.02.021.
  • Habot-Wilner Z, Noronha G, Wykoff CC. Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach. Acta Ophthalmol. 2019;97(5):460–472. doi:10.1111/aos.14042.
  • Hancock SE, Wan CR, Fisher NE, et al. Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies. Expert Opinion on Drug Delivery 2021;1–12. doi:10.1080/17425247.2021.1867532.
  • Wan C-R, Muya L, Kansara V, et al. Suprachoroidal delivery of small molecules, nanoparticles, gene and cell therapies for ocular diseases. Pharmaceutics. 2021;13(2):288. doi:10.3390/pharmaceutics13020288.
  • Yeh S, Khurana RN, Shah M, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: phase 3, Randomized Trial (PEACHTREE). Ophthalmology. 2020;127(7):948–955. doi:10.1016/j.ophtha.2020.01.006.
  • Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553. doi:10.1001/archophthalmol.2010.339.
  • Jaffe GJ, Foster CS, Pavesio CE, et al. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology. 2019;126(4):601–610. doi:10.1016/j.ophtha.2018.10.033.
  • Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the periocular vs. intravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology. 2019;126(2):283–295. doi:10.1016/j.ophtha.2018.08.021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.